A borderline ovarian tumor (BOT) is a low malignant potential tumor characterized by slow-growing without invading other tissue. It accounts for 15% of epithelial ovarian tumors and can be divided into different histotypes: mucinous (MBOTs), serous (SBOTs), endometrioid, clear cell, brenner, and others. The vast majority of BOTs are often limited to one or both sides of the ovary. The 75% of BOT is diagnosed at an early stage. In these cases, the prognosis is good, with a 10-year survival rate of about 95%. Recurrence or transformation into low-grade serous ovarian carcinoma (LGSOC) is reported in a few patients. The primary treatment method of BOTs is surgery, which should be tailored according to patients’ age, fertility requirements, pathological stage, and pathological types. Adjuvant chemotherapy is generally not recommended since BOTS have a poor response to chemotherapy.
Our purpose is to report the most recent knowledge on the management of borderline ovarian tumors, looking at young women seeking fertility-sparing treatment. Moreover, in the era of precision medicine, it is crucial to tailor the therapy according to patients’ characteristics: age, desire for fertility, pathological stage, and histotypes.
We are looking for original articles, including retrospective, prospective, or randomized clinical trials, and review articles, especially systematic with metanalysis. Only very interesting case reports will be taken into account.
A borderline ovarian tumor (BOT) is a low malignant potential tumor characterized by slow-growing without invading other tissue. It accounts for 15% of epithelial ovarian tumors and can be divided into different histotypes: mucinous (MBOTs), serous (SBOTs), endometrioid, clear cell, brenner, and others. The vast majority of BOTs are often limited to one or both sides of the ovary. The 75% of BOT is diagnosed at an early stage. In these cases, the prognosis is good, with a 10-year survival rate of about 95%. Recurrence or transformation into low-grade serous ovarian carcinoma (LGSOC) is reported in a few patients. The primary treatment method of BOTs is surgery, which should be tailored according to patients’ age, fertility requirements, pathological stage, and pathological types. Adjuvant chemotherapy is generally not recommended since BOTS have a poor response to chemotherapy.
Our purpose is to report the most recent knowledge on the management of borderline ovarian tumors, looking at young women seeking fertility-sparing treatment. Moreover, in the era of precision medicine, it is crucial to tailor the therapy according to patients’ characteristics: age, desire for fertility, pathological stage, and histotypes.
We are looking for original articles, including retrospective, prospective, or randomized clinical trials, and review articles, especially systematic with metanalysis. Only very interesting case reports will be taken into account.
